32,772 Shares in Janux Therapeutics, Inc. $JANX Purchased by Capital Fund Management S.A.

Capital Fund Management S.A. purchased a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 32,772 shares of the company’s stock, valued at approximately $757,000. Capital Fund Management S.A. owned 0.05% of Janux Therapeutics at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. US Bancorp DE increased its holdings in shares of Janux Therapeutics by 2,402.9% during the 1st quarter. US Bancorp DE now owns 1,727 shares of the company’s stock valued at $47,000 after purchasing an additional 1,658 shares in the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Janux Therapeutics by 25.6% during the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after buying an additional 820 shares in the last quarter. FNY Investment Advisers LLC grew its position in Janux Therapeutics by 111.8% during the second quarter. FNY Investment Advisers LLC now owns 5,210 shares of the company’s stock valued at $120,000 after buying an additional 2,750 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Janux Therapeutics by 26.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,125 shares of the company’s stock valued at $192,000 after buying an additional 1,488 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its position in shares of Janux Therapeutics by 29.5% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,054 shares of the company’s stock worth $209,000 after acquiring an additional 2,060 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Performance

Shares of JANX opened at $16.51 on Friday. The stock has a 50 day moving average price of $26.79 and a 200 day moving average price of $25.20. Janux Therapeutics, Inc. has a one year low of $15.51 and a one year high of $68.99. The stock has a market capitalization of $993.08 million, a price-to-earnings ratio of -9.83 and a beta of 2.82.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.21. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.07 million. On average, analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on JANX. UBS Group restated a “buy” rating and set a $57.00 target price on shares of Janux Therapeutics in a research report on Tuesday. Wedbush reissued an “outperform” rating and issued a $45.00 price objective (down from $76.00) on shares of Janux Therapeutics in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Wednesday, October 8th. Bank of America dropped their price target on shares of Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, HC Wainwright cut their price target on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $62.67.

Insiders Place Their Bets

In related news, insider Andrew Hollman Meyer sold 16,665 shares of the company’s stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $30.06, for a total transaction of $500,949.90. Following the completion of the sale, the insider owned 82,139 shares of the company’s stock, valued at approximately $2,469,098.34. This represents a 16.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 23,331 shares of company stock worth $710,862 in the last quarter. Insiders own 8.10% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.